Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-6-26
pubmed:abstractText
We conducted a phase II randomized study to assess the efficacy, with response as the primary endpoint, and the toxicity of gemcitabine/cisplatin (GP) and gemcitabine/carboplatin (GC) in patients with advanced non-small cell lung cancer (NSCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0169-5002
pubmed:author
pubmed:issnType
Print
pubmed:volume
41
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
81-9
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:12826316-Adolescent, pubmed-meshheading:12826316-Adult, pubmed-meshheading:12826316-Aged, pubmed-meshheading:12826316-Antimetabolites, Antineoplastic, pubmed-meshheading:12826316-Antineoplastic Agents, pubmed-meshheading:12826316-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12826316-Carboplatin, pubmed-meshheading:12826316-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:12826316-Cisplatin, pubmed-meshheading:12826316-Deoxycytidine, pubmed-meshheading:12826316-Female, pubmed-meshheading:12826316-Humans, pubmed-meshheading:12826316-Lung Neoplasms, pubmed-meshheading:12826316-Male, pubmed-meshheading:12826316-Middle Aged, pubmed-meshheading:12826316-Prognosis, pubmed-meshheading:12826316-Prospective Studies, pubmed-meshheading:12826316-Survival Rate, pubmed-meshheading:12826316-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
pubmed:affiliation
Department of Medical Oncology, Azienda Ospedaliera Umberto I, via Conca, 60122 Torrette di Ancona, Italy. p.mazzanti@ao-umbertoprimo.marche.it
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II